Sign Out
Click on icon to see table/diagram/imageMaintenance dose: Dose should be individualized for each patient upon reaching the target hematocrit range.
Mode of Administration: Intravenous and Subcutaneous administration.
Information to Patients: The dose Renogen should be reduced as the hematocrit level approaches 36% or has increased by more than 4 points in any 2-week period.
Renogen should be given through intravenous and subcutaneous administration only.
Do not shake. Vigorous shaking of Renogen may denature any glycoprotein, rendering it biologically inactive. Do not use if there is any particulate matter or discoloration.
Using aseptic techniques, attach a sterile needle to a sterile syringe.
Remove the flip top from the vial containing Renogen and wipe the septum with a disinfectant. Insert the needle into the vial, and withdraw into the syringe an appropriate volume of solution.
Renogen does not contain any preservatives: discard unused portions.
Do not dilute or administer with other drug solutions.
Continue with Google